Climb Bio (NASDAQ:CLYM – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Royal Bank Of Canada in a research note issued on Wednesday, MarketBeat.com reports. They presently have a $23.00 price objective on the stock. Royal Bank Of Canada‘s price objective suggests a potential upside of 147.84% from the company’s previous close.
A number of other brokerages have also recently issued reports on CLYM. Wedbush lifted their price objective on Climb Bio from $25.00 to $27.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Climb Bio in a report on Thursday, November 5th. Piper Sandler reiterated an “overweight” rating on shares of Climb Bio in a research report on Tuesday, October 27th. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Climb Bio in a report on Tuesday, October 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Climb Bio in a report on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $28.14.
View Our Latest Stock Report on CLYM
Climb Bio Stock Performance
Climb Bio (NASDAQ:CLYM – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.02. On average, research analysts predict that Climb Bio will post -0.75 earnings per share for the current year.
Insider Activity
In other Climb Bio news, Director Stephen Thomas sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the transaction, the director owned 467,969 shares in the company, valued at approximately $6,397,136.23. This trade represents a 17.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.60% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of CLYM. Goldman Sachs Group Inc. raised its holdings in shares of Climb Bio by 535.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 528,535 shares of the company’s stock valued at $6,062,000 after purchasing an additional 445,305 shares during the period. Integral Health Asset Management LLC bought a new position in Climb Bio during the third quarter worth about $8,029,000. Marshall Wace LLP bought a new position in Climb Bio during the third quarter worth about $6,406,000. Empowered Funds LLC bought a new position in Climb Bio during the third quarter worth about $265,000. Finally, First Trust Advisors LP acquired a new position in Climb Bio during the third quarter worth approximately $490,000. Institutional investors own 69.76% of the company’s stock.
About Climb Bio
Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.
Further Reading
- Five stocks we like better than Climb Bio
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
